Trends in <scp>HCV</scp> treatment uptake, efficacy and impact on liver fibrosis in the Swiss <scp>HIV</scp> Cohort Study

Béguelin, Charles; Suter, Annatina; Bernasconi, Enos; Fehr, Jan; Kovari, Helen; Bucher, Heiner C.; Stoeckle, Marcel; Cavassini, Matthias; Rougemont, Mathieu; Schmid, Patrick; Wandeler, Gilles; Rauch, Andri

doi:10.1111/liv.13528

Cited by 26 publications

(22 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data are from 2014 to 2015. Second‐generation DAAs were available but restricted by liver disease stage .…”

Section: Results ‐ Progress Toward Hcv Elimination In Hiv‐infected Pomentioning

confidence: 99%

“…Population-wide proportions of those diagnosed with HIV/HCV co-infection who have received treatment are likely to be lower than those presented here. HCV diagnosis rates among HIV-infected populations are not currently well understood and additional research is required to estimate [42]. c Cascade of care from the ATHENA cohort of people diagnosed with HIV in the Netherlands from a period where DAAs were broadly available but prior to MC Free, Amsterdam [45].…”

Section: Discussionmentioning

confidence: 99%

“…This represents a substantially higher treatment uptake than prior to DAA therapies becoming available. In the Swiss HIV cohorts, treatment uptake increased fourfold after the introduction of second‐generation DAAs . In Georgia, approximately 100 HCV/HIV co‐infected people were treated per year in the three and a half years prior to DAA availability, compared to approximately 265 treatments/year in the first 15 months of the nationwide HCV elimination programme .…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

et al. 2018

Self Cite

View full text Add to dashboard Cite

IntroductionThere is currently no published data on the effectiveness of DAA treatment for elimination of HCV infection in HIV‐infected populations at a population level. However, a number of relevant studies and initiatives are emerging. This research aims to report cascade of care data for emerging HCV elimination initiatives and studies that are currently being evaluated in HIV/HCV co‐infected populations in the context of implementation science theory.Methods HCV elimination initiatives and studies in HIV co‐infected populations that are currently underway were identified. Context, intervention characteristics and cascade of care data were synthesized in the context of implementation science frameworks.ResultsSeven HCV elimination initiatives and studies were identified in HIV co‐infected populations, mainly operating in high‐income countries. Four were focused mainly on HCV elimination in HIV‐infected gay and bisexual men (GBM), and three included a combination of people who inject drugs (PWID), GBM and other HIV‐infected populations. None were evaluating treatment delivery in incarcerated populations. Overall, HCV RNA was detected in 4894 HIV‐infected participants (range within studies: 297 to 994): 48% of these initiated HCV treatment (range: 21% to 85%; within studies from a period where DAAs were broadly available the total is 57%, range: 36% to 74%). Among studies with treatment completion data, 96% of 1109 initiating treatment completed treatment (range: 94% to 99%). Among those who could be assessed for sustained virological response at 12 weeks (SVR12), 1631 of 1757 attained SVR12 (93%, range: 86% to 98%).ConclusionsEarly results from emerging research on HCV elimination in HIV‐infected populations suggest that HCV treatment uptake is higher than reported levels prior to DAA treatment availability, but approximately half of patients remain untreated. These results are among diagnosed populations and additional effort is required to increase diagnosis rates. Among those who have initiated treatment, completion and SVR rates are promising. More data are required in order to evaluate the effectiveness of these elimination programmes in the long term, assess which intervention components are effective, and whether they need to be tailored to particular population groups.

show abstract

“…Data are from 2014 to 2015. Second‐generation DAAs were available but restricted by liver disease stage .…”

Section: Results ‐ Progress Toward Hcv Elimination In Hiv‐infected Pomentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Detailed clinical and laboratory data were recorded at study entry and every 6 months thereafter. HCV infection assessments included yearly serology followed by HCV RNA determination in seropositive individuals, as well as a detailed treatment history, as described previously [ 3 ].…”

Section: Methodsmentioning

confidence: 99%

“…Achieving a sustained virological response (SVR) substantially reduces HCV-related mortality and morbidity and prevents further HCV transmission [ 2 ]. After the approval of interferon-free second-generation direct-acting antivirals (DAAs) in Switzerland, we observed a 4-fold increase in treatment uptake and a 2-fold increase in treatment efficacy, with an SVR rate above 90% across all HCV genotypes [ 3 ]. Previous modeling studies indicated that a major increase in DAA treatment uptake has the potential to curb the HCV epidemic [ 4 , 5 ].…”

mentioning

confidence: 99%

Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study

Salazar‐Vizcaya

Wandeler

Fehr

et al. 2018

Open Forum Infectious Diseases

Self Cite

View full text Add to dashboard Cite

show abstract

Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort

Baum

Tamargo

Ehman

et al. 2021

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study

Abstract: After the introduction of second-generation DAAs, we observed an increase in treatment uptake and efficacy which resulted in a significant reduction in the number of cirrhotic patients with a replicating HCV infection in the SHCS.

Cited by 26 publications

References 33 publications

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study

Heroin use is associated with liver fibrosis in the Miami Adult Studies on HIV (MASH) cohort

Contact Info

Product

Resources

About